{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:44:50Z","timestamp":1795275890001,"version":"4.10.3"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    TDP-43 is an RNA-binding protein with a crucial nuclear role in splicing, and mislocalises from the nucleus to the cytoplasm in a range of neurodegenerative disorders. TDP-43 proteinopathy spans a spectrum of incurable, heterogeneous, and increasingly prevalent neurodegenerative diseases, including the amyotrophic lateral sclerosis and frontotemporal dementia disease spectrum and a significant fraction of Alzheimer\u2019s disease. There are currently no directed disease-modifying therapies for TDP-43 proteinopathies, and no way to distinguish who is affected before death. It is now clear that TDP-43 proteinopathy leads to a number of molecular changes, including the de-repression and inclusion of cryptic exons. Importantly, some of these cryptic exons lead to the loss of crucial neuronal proteins and have been shown to be key pathogenic players in disease pathogenesis (e.g.\n                    <jats:italic>, STMN2<\/jats:italic>\n                    ), as well as being able to modify disease progression (e.g.\n                    <jats:italic>, UNC13A<\/jats:italic>\n                    ). Thus, these aberrant splicing events make promising novel therapeutic targets to restore functional gene expression. Moreover, presence of these cryptic exons is highly specific to patients and areas of the brain affected by TDP-43 proteinopathy, offering the potential to develop biomarkers for early detection and stratification of patients. In summary, the discovery of cryptic exons gives hope for novel diagnostics and therapeutics on the horizon for TDP-43 proteinopathies.\n                  <\/jats:p>","DOI":"10.1186\/s13024-023-00608-5","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:38:17Z","timestamp":1679848697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["The era of cryptic exons: implications for ALS-FTD"],"prefix":"10.1186","volume":"18","author":[{"given":"Puja R.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Leigh","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-1632","authenticated-orcid":false,"given":"Pietro","family":"Fratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"608_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u20133.","journal-title":"Science"},{"key":"608_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","volume":"1184","author":"S Higashi","year":"2007","unstructured":"Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007;1184:284\u201394.","journal-title":"Brain Res"},{"key":"608_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","volume":"92","author":"EMJ de Boer","year":"2020","unstructured":"de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92:86\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"608_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/nen.0b013e31803020b9","volume":"66","author":"M Neumann","year":"2007","unstructured":"Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152\u20137.","journal-title":"J Neuropathol Exp Neurol"},{"key":"608_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.brainres.2008.10.021","volume":"1249","author":"K Moisse","year":"2009","unstructured":"Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009;1249:202\u201311.","journal-title":"Brain Res"},{"key":"608_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.expneurol.2017.09.011","volume":"299","author":"D Wiesner","year":"2018","unstructured":"Wiesner D, Tar L, Linkus B, Chandrasekar A, Olde Heuvel F, Dupuis L, et al. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp Neurol. 2018;299:15\u201325.","journal-title":"Exp Neurol"},{"key":"608_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroscience.2015.05.013","volume":"300","author":"HK Wang","year":"2015","unstructured":"Wang HK, Lee YC, Huang CY, Liliang PC, Lu K, Chen HJ, et al. Traumatic brain injury causes frontotemporal dementia and TDP-43 proteolysis. Neuroscience. 2015;300:94\u2013103.","journal-title":"Neuroscience"},{"key":"608_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-022-02449-w","volume":"144","author":"F Gao","year":"2022","unstructured":"Gao F, Hu M, Zhang J, Hashem J, Chen C. TDP-43 drives synaptic and cognitive deterioration following traumatic brain injury. Acta Neuropathol. 2022;144:187\u2013210.","journal-title":"Acta Neuropathol"},{"key":"608_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1212\/01.WNL.0000049472.47709.3B","volume":"60","author":"MA del Aguila","year":"2003","unstructured":"del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60:813\u20139.","journal-title":"Neurology"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","volume":"65","author":"GM Ringholz","year":"2005","unstructured":"Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586\u201390.","journal-title":"Neurology"},{"key":"608_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1474-4422(10)70195-2","volume":"9","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995\u20131007.","journal-title":"Lancet Neurol"},{"key":"608_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ng.132","volume":"40","author":"E Kabashi","year":"2008","unstructured":"Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572\u20134.","journal-title":"Nat Genet"},{"key":"608_CR14","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","volume":"319","author":"J Sreedharan","year":"2008","unstructured":"Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668\u201372.","journal-title":"Science"},{"key":"608_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.aab0983","volume":"349","author":"JP Ling","year":"2015","unstructured":"Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650\u20135.","journal-title":"Science"},{"key":"608_CR16","doi-asserted-by":"publisher","first-page":"36337","DOI":"10.1074\/jbc.M104236200","volume":"276","author":"E Buratti","year":"2001","unstructured":"Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337\u201343.","journal-title":"J Biol Chem"},{"key":"608_CR17","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1111\/j.1742-4658.2010.07643.x","volume":"277","author":"E Buratti","year":"2010","unstructured":"Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 2010;277:2268\u201381.","journal-title":"FEBS J"},{"key":"608_CR18","doi-asserted-by":"publisher","first-page":"21510","DOI":"10.1073\/pnas.1211577110","volume":"109","author":"M Prudencio","year":"2012","unstructured":"Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang YJ, Xu YF, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A. 2012;109:21510\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"608_CR19","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/nar\/gkr1082","volume":"40","author":"FC Fiesel","year":"2012","unstructured":"Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ. TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. Nucleic Acids Res. 2012;40:2668\u201382.","journal-title":"Nucleic Acids Res"},{"key":"608_CR20","doi-asserted-by":"publisher","first-page":"e43120","DOI":"10.1371\/journal.pone.0043120","volume":"7","author":"A Shiga","year":"2012","unstructured":"Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One. 2012;7:e43120.","journal-title":"PLoS One"},{"key":"608_CR21","doi-asserted-by":"publisher","first-page":"33996","DOI":"10.1038\/srep33996","volume":"6","author":"S Prpar Mihevc","year":"2016","unstructured":"Prpar Mihevc S, Baralle M, Buratti E, Rogelj B. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep. 2016;6:33996.","journal-title":"Sci Rep"},{"key":"608_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/hmg\/ddv491","volume":"25","author":"F Mohagheghi","year":"2016","unstructured":"Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW, et al. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum Mol Genet. 2016;25:534\u201345.","journal-title":"Hum Mol Genet"},{"key":"608_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","volume":"22","author":"JR Klim","year":"2019","unstructured":"Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167\u201379.","journal-title":"Nat Neurosci"},{"key":"608_CR24","doi-asserted-by":"publisher","first-page":"e201900358","DOI":"10.26508\/lsa.201900358","volume":"2","author":"A Roczniak-Ferguson","year":"2019","unstructured":"Roczniak-Ferguson A, Ferguson SM. Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci Alliance. 2019;2:e201900358.","journal-title":"Life Sci Alliance"},{"key":"608_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s42003-022-03253-8","volume":"5","author":"U Susnjar","year":"2022","unstructured":"Susnjar U, Skrabar N, Brown AL, Abbassi Y, Phatnani H, Consortium NA, et al. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease. Commun Biol. 2022;5:314.","journal-title":"Commun Biol"},{"key":"608_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn.2778","volume":"14","author":"JR Tollervey","year":"2011","unstructured":"Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452\u20138.","journal-title":"Nat Neurosci"},{"key":"608_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nn.2779","volume":"14","author":"M Polymenidou","year":"2011","unstructured":"Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459\u201368.","journal-title":"Nat Neurosci"},{"key":"608_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00401-017-1701-2","volume":"133","author":"M Sun","year":"2017","unstructured":"Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, et al. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 2017;133:923\u201331.","journal-title":"Acta Neuropathol"},{"key":"608_CR29","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1080\/15548627.2018.1474311","volume":"14","author":"P Torres","year":"2018","unstructured":"Torres P, Ramirez-Nunez O, Romero-Guevara R, Bares G, Granado-Serrano AB, Ayala V, et al. Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue. Autophagy. 2018;14:1398\u2013403.","journal-title":"Autophagy"},{"key":"608_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180\u201390.","journal-title":"Nat Neurosci"},{"key":"608_CR31","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1172\/JCI139741","volume":"130","author":"M Prudencio","year":"2020","unstructured":"Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130:6080\u201392.","journal-title":"J Clin Invest"},{"key":"608_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","volume":"603","author":"AL Brown","year":"2022","unstructured":"Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131\u20137.","journal-title":"Nature"},{"key":"608_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124\u201330.","journal-title":"Nature"},{"key":"608_CR34","doi-asserted-by":"publisher","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","volume":"14","author":"KA Britson","year":"2022","unstructured":"Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14:eabi9196.","journal-title":"Sci Transl Med"},{"key":"608_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-016-0144-x","volume":"12","author":"YH Jeong","year":"2017","unstructured":"Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, et al. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017;12:13.","journal-title":"Mol Neurodegener"},{"key":"608_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrm4063","volume":"16","author":"S Lykke-Andersen","year":"2015","unstructured":"Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16:665\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.celrep.2019.04.003","volume":"27","author":"EY Liu","year":"2019","unstructured":"Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with Decondensation of LINE retrotransposons. Cell Rep. 2019;27:1409\u201321 e1406.","journal-title":"Cell Rep"},{"key":"608_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/ng.442","volume":"41","author":"MA van Es","year":"2009","unstructured":"van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083\u20137.","journal-title":"Nat Genet"},{"key":"608_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/22768","volume":"400","author":"I Augustin","year":"1999","unstructured":"Augustin I, Rosenmund C, Sudhof TC, Brose N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457\u201361.","journal-title":"Nature"},{"key":"608_CR40","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1212\/NXG.0000000000000105","volume":"2","author":"AG Engel","year":"2016","unstructured":"Engel AG, Selcen D, Shen XM, Milone M, Harper CM. Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurol Genet. 2016;2:e105.","journal-title":"Neurol Genet"},{"issue":"630","key":"608_CR41","first-page":"e633","volume":"33","author":"FP Diekstra","year":"2012","unstructured":"Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(630):e633\u20138.","journal-title":"Neurobiol Aging"},{"issue":"357","key":"608_CR42","first-page":"e351","volume":"34","author":"A Chio","year":"2013","unstructured":"Chio A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging. 2013;34(357):e351\u20135.","journal-title":"Neurobiol Aging"},{"key":"608_CR43","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s00415-015-7843-z","volume":"262","author":"JM Vidal-Taboada","year":"2015","unstructured":"Vidal-Taboada JM, Lopez-Lopez A, Salvado M, Lorenzo L, Garcia C, Mahy N, et al. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol. 2015;262:2285\u201392.","journal-title":"J Neurol"},{"key":"608_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/21678421.2016.1213852","volume":"17","author":"B Gaastra","year":"2016","unstructured":"Gaastra B, Shatunov A, Pulit S, Jones AR, Sproviero W, Gillett A, et al. Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:593\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"608_CR45","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s10072-019-03951-y","volume":"40","author":"B Yang","year":"2019","unstructured":"Yang B, Jiang H, Wang F, Li S, Wu C, Bao J, et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol Sci. 2019;40:2293\u2013302.","journal-title":"Neurol Sci"},{"key":"608_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2018.09.031","volume":"73","author":"K Placek","year":"2019","unstructured":"Placek K, Baer GM, Elman L, McCluskey L, Hennessy L, Ferraro PM, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2019;73:190\u20139.","journal-title":"Neurobiol Aging"},{"key":"608_CR47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ana.25841","volume":"88","author":"HHG Tan","year":"2020","unstructured":"Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, et al. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol. 2020;88:796\u2013806.","journal-title":"Ann Neurol"},{"key":"608_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","volume":"88","author":"SR Shepheard","year":"2017","unstructured":"Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137\u201343.","journal-title":"Neurology"},{"key":"608_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00415-017-8730-6","volume":"265","author":"D Rossi","year":"2018","unstructured":"Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510\u201321.","journal-title":"J Neurol"},{"key":"608_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"608_CR51","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/01.wco.0000186842.51129.cb","volume":"18","author":"SM Henley","year":"2005","unstructured":"Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol. 2005;18:698\u2013705.","journal-title":"Curr Opin Neurol"},{"key":"608_CR52","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1073\/pnas.1405528111","volume":"111","author":"W Koh","year":"2014","unstructured":"Koh W, Pan W, Gawad C, Fan HC, Kerchner GA, Wyss-Coray T, et al. Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proc Natl Acad Sci U S A. 2014;111:7361\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"608_CR53","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.1232927","volume":"339","author":"K Mori","year":"2013","unstructured":"Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS. Science. 2013;339:1335\u20138.","journal-title":"Science"},{"key":"608_CR54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","volume":"77","author":"PE Ash","year":"2013","unstructured":"Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS. Neuron. 2013;77:639\u201346.","journal-title":"Neuron"},{"key":"608_CR55","doi-asserted-by":"publisher","first-page":"eaai7866","DOI":"10.1126\/scitranslmed.aai7866","volume":"9","author":"TF Gendron","year":"2017","unstructured":"Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaai7866.","journal-title":"Sci Transl Med"},{"key":"608_CR56","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.neuron.2019.11.007","volume":"105","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, Montrasio F, Pattamatta A, Tusi SK, Bardhi O, Meyer KD, et al. Antibody therapy targeting RAN proteins rescues C9 ALS\/FTD phenotypes in C9orf72 mouse model. Neuron. 2020;105:645\u201362 e611.","journal-title":"Neuron"},{"key":"608_CR57","doi-asserted-by":"crossref","unstructured":"Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv. 2023 2023.2001.2023.525202.","DOI":"10.1101\/2023.01.23.525202"},{"key":"608_CR58","doi-asserted-by":"crossref","unstructured":"Seddighi S, Qi YA, Brown A-L, Wilkins OG, Bereda C, Belair C, et al. Mis-spliced transcripts generate de novo\u00a0proteins in TDP-43-related ALS\/FTD. bioRxiv. 2023 2023.2001.2023.525149.","DOI":"10.1101\/2023.01.23.525149"},{"key":"608_CR59","doi-asserted-by":"crossref","unstructured":"Iannitelli DE, Tan A, Nguyen E, Babu A, Elorza SD, Joseph T, et al. ALS sensitive spinal motor neurons enter a degenerative downward spiral of impaired splicing and proteostasis. bioRxiv. 2022 2022.2003.2026.485939.","DOI":"10.1101\/2022.03.26.485939"},{"key":"608_CR60","doi-asserted-by":"publisher","first-page":"e75230","DOI":"10.7554\/eLife.75230","volume":"11","author":"D Heo","year":"2022","unstructured":"Heo D, Ling JP, Molina-Castro GC, Langseth AJ, Waisman A, Nave KA, et al. Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43. Elife. 2022;11:e75230.","journal-title":"Elife"},{"key":"608_CR61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-014-1299-6","volume":"128","author":"J Brettschneider","year":"2014","unstructured":"Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423\u201337.","journal-title":"Acta Neuropathol"},{"key":"608_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000362929","volume":"14","author":"Z Rohan","year":"2014","unstructured":"Rohan Z, Matej R, Rusina R, Kovacs GG. Oligodendroglial response in the spinal cord in TDP-43 proteinopathy with motor neuron involvement. Neurodegener Dis. 2014;14:117\u201324.","journal-title":"Neurodegener Dis"},{"key":"608_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awab285","volume":"145","author":"N Riva","year":"2022","unstructured":"Riva N, Gentile F, Cerri F, Gallia F, Podini P, Dina G, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145:276\u201384.","journal-title":"Brain"},{"issue":"1","key":"608_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cjp2.297","volume":"9","author":"SB Pattle","year":"2022","unstructured":"Pattle SB, O'Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, et al. pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies with clinical phenotypic data. J Pathol Clin Res. 2022;9(1):44\u201355.","journal-title":"J Pathol Clin Res"},{"key":"608_CR65","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1093\/brain\/aww250","volume":"139","author":"SC Vatsavayai","year":"2016","unstructured":"Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139:3202\u201316.","journal-title":"Brain"},{"key":"608_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41591-021-01629-7","volume":"28","author":"ER Lopez","year":"2022","unstructured":"Lopez ER, Borschel WF, Traynor BJ. New antisense oligonucleotide therapies reach first base in ALS. Nat Med. 2022;28:25\u20137.","journal-title":"Nat Med"},{"key":"608_CR67","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.neuron.2022.02.011","volume":"110","author":"I Guerra San Juan","year":"2022","unstructured":"Guerra San Juan I, Nash LA, Smith KS, Leyton-Jaimes MF, Qian M, Klim JR, et al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron. 2022;110:1671\u201388 e1676.","journal-title":"Neuron"},{"key":"608_CR68","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930\u201340.","journal-title":"Nat Neurosci"},{"key":"608_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53.","journal-title":"Signal Transduct Target Ther"},{"key":"608_CR70","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099\u2013110.","journal-title":"N Engl J Med"},{"key":"608_CR71","unstructured":"Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis [https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-1-study-results]."},{"key":"608_CR72","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"608_CR73","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY. Eteplirsen: first global approval. Drugs. 2016;76:1699\u2013704.","journal-title":"Drugs"},{"key":"608_CR74","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/genes13071241","volume":"13","author":"G Eser","year":"2022","unstructured":"Eser G, Topaloglu H. Current outline of exon skipping trials in Duchenne muscular dystrophy. Genes (Basel). 2022;13:1241.","journal-title":"Genes (Basel)"},{"key":"608_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.26259","volume":"91","author":"D Ito","year":"2022","unstructured":"Ito D. Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis. Ann Neurol. 2022;91:13\u201320.","journal-title":"Ann Neurol"},{"key":"608_CR76","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","volume":"173","author":"S Konermann","year":"2018","unstructured":"Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173:665\u201376 e614.","journal-title":"Cell"},{"key":"608_CR77","doi-asserted-by":"publisher","first-page":"e3321","DOI":"10.1002\/jgm.3321","volume":"23","author":"A Gadgil","year":"2021","unstructured":"Gadgil A, Raczynska KD. U7 snRNA: a tool for gene therapy. J Gene Med. 2021;23:e3321.","journal-title":"J Gene Med"},{"key":"608_CR78","first-page":"1317","volume":"32","author":"D Lesman","year":"2021","unstructured":"Lesman D, Rodriguez Y, Rajakumar D, Wein N. U7 snRNA, a small RNA with a big impact in gene therapy. Hum Gene Ther. 2021;32:1317\u201329.","journal-title":"Hum Gene Ther"},{"key":"608_CR79","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345:688\u201393.","journal-title":"Science"},{"key":"608_CR80","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd.2018.93","volume":"17","author":"KD Warner","year":"2018","unstructured":"Warner KD, Hajdin CE, Weeks KM. Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018;17:547\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"608_CR81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427\u201335.","journal-title":"N Engl J Med"},{"key":"608_CR82","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","volume":"12","author":"H Ratni","year":"2021","unstructured":"Ratni H, Scalco RS, Stephan AH. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med Chem Lett. 2021;12:874\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"608_CR83","unstructured":"QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference [https:\/\/quralis.com\/quralis-presents-data-about-stathmin-2-role-in-neuronal-disease-biology-and-tdp-43-biomarker-identification-at-ad-pd-2022\/]."},{"key":"608_CR84","first-page":"10","volume":"2019","author":"F Zhu","year":"1845","unstructured":"Zhu F, Nair RR, Fisher EMC, Cunningham TJ. Humanising the mouse genome piece by piece. Nat Commun. 1845;2019:10.","journal-title":"Nat Commun"},{"key":"608_CR85","unstructured":"The Jackson Laboratory. C57BL\/6J-Stmn2em6(STMN2)Lutzy\/Mmjax [https:\/\/www.jax.org\/strain\/034061]."}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-023-00608-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:41:15Z","timestamp":1679848875000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-023-00608-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1186\/s13024-023-00608-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent application related to this work has been filed. The technology described in this work has been protected in the patent PCT\/EP2021\/084908 and UK patent 2117758.9 (patent applicant, UCL Business Ltd. and NIH; status pending), in which AL-B, MEW, and PF are named as inventors. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}